Peter Barton Hutt is Director of CONCERT PHARMACEUTICALS, INC.. Currently has a direct ownership of 0 shares of CNCE, which is worth approximately $0. The most recent transaction as insider was on Mar 06, 2023, when has been sold 13,088 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 0
0% 3M change
0% 12M change
Total Value Held $0

PETER BARTON HUTT Transaction History

Date Transaction Value Shares Traded Shares Held Form
Mar 06 2023
SELL
Disposition due to a tender of shares in a change of control transaction
-
13,088 Reduced 100.0%
0 Common Stock
Mar 06 2023
SELL
Sale (or disposition) back to the issuer
-
16,400 Reduced 100.0%
0 Common Stock
Oct 14 2022
SELL
Open market or private sale
$21,553 $6.09 p/Share
3,539 Reduced 10.72%
29,488 Common Stock
Oct 14 2022
BUY
Exercise of conversion of derivative security
$10,192 $2.88 p/Share
3,539 Added 9.68%
33,027 Common Stock
Jun 09 2022
BUY
Grant, award, or other acquisition
-
16,400 Added 35.74%
29,488 Common Stock
Jun 10 2021
BUY
Grant, award, or other acquisition
-
5,125 Added 28.14%
13,088 Common Stock

Also insider at

MRNA
Moderna, Inc. Healthcare
IMMU
IMMUNOMEDICS INC
PBH

Peter Barton Hutt

Director
Cambridge, MA

Track Institutional and Insider Activities on CNCE

Follow CONCERT PHARMACEUTICALS, INC. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CNCE shares.

Notify only if

Insider Trading

Get notified when an Concert Pharmaceuticals, Inc. insider buys or sells CNCE shares.

Notify only if

News

Receive news related to CONCERT PHARMACEUTICALS, INC.

Track Activities on CNCE